Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3655 |
BMS-1
PD1-PDL1 inhibitor 1,PD-1/PD-L1 inhibitor 1 |
Apoptosis; PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
BMS-1 (PD-1/PD-L1 inhibitor 1)是一种 PD-1/PD-L1蛋白质/蛋白质相互作用的抑制剂,IC50为 6 到 100 nM。 | |||
T9616 |
PD-1/PD-L1-IN-10
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
PD-1/PD-L1-IN-10 是一种口服有效的PD-1/PD-L1抑制剂 (IC50of 2.7 nM),显示出抗肿瘤活性。 | |||
T4696 |
BMS202 hydrochloride (1675203-84-5(free base))
PD-1/PD-L1 inhibitor 2 hydrochloride |
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) 是一种小分子 PD-1/PD-L1 相互作用抑制剂 (IC50: 18 nM)。生物物理研究表明 BMS202 直接与 PD-L1 结合。 BMS202 的结合促进 PD-L1 二聚化并阻断 PD-L1/PD1 相互作用。 | |||
T3146 |
BMS-202
PD1-PDL1 inhibitor 2,PD-1/PD-L1 inhibitor 2 |
Apoptosis; PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
BMS-202 (PD1-PDL1 inhibitor 2) 是一种非肽类 PD-1/PD-L 复合物抑制剂,其 IC50为 18 nM,KD 为 8 μM。它与 PD-L1 直接结合并阻断人类 PD-1/PD-L 的相互作用,具有抗肿瘤活性。 | |||
T26859 |
BMS-8
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
BMS-8 抑制PD-1/PD-L1相互作用(IC50:7.2 μM)。它能够直接与 PD-L1 结合,促使形成 PD-L1 同源二聚体,进而阻断 PD-L1 与 PD-1 的相互作用。 | |||
T21737L | PD-1/PD-L1 Inhibitor 3 acetate (1629654-95-0 Free base) | ||
T39591 |
Human PD-L1 inhibitor I
Human PD-L1 inhibitor I |
||
Human PD-L1 inhibitor I is a peptide ligand that specifically inhibits the interaction between human PD-L1 and human PD-1. It exhibits a KD value of 3.39 μM, indicating its binding affinity. The presence of Human PD-L1 inhibitor I disrupts the binding between human PD-L1 and human PD-1, thereby attenuating their respective functions. | |||
T39588 |
Human PD-L1 inhibitor IV
Human PD-L1 inhibitor IV |
||
Human PD-L1 inhibitor IV is a polypeptide compound that competitively inhibits the human PD-1 protein. It has a Kd value of 1.38 μM and effectively blocks the interaction between hPD-1 and hPD-L1. | |||
T39589 |
Human PD-L1 inhibitor III
Human PD-L1 inhibitor III |
||
Human PD-L1 inhibitor III is a human PD-L1 inhibitor. | |||
T39590 |
Human PD-L1 inhibitor II
Human PD-L1 inhibitor II |
||
Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity. | |||
T36487 |
Evixapodlin
PD-1/PD-L1-IN 7,GS-4224 |
Antiviral; HBV; PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation; Microbiology/Virology |
Evixapodlin (PD-1/PD-L1-IN 7) 是一种人 PD-1/PD-L1蛋白/蛋白相互作用抑制剂(IC50:0.213)。Evixapodlin 具有抗癌和抗病毒活性。 | |||
T83976 |
ARB-272572 hydrochloride
ARB-272572 hydrochloride(2368182-63-0 Free base) |
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
ARB-272572 hydrochloride 是一种小分子 PD-L1 抑制剂,对PD-1/PD-L1 HTRF的 IC50 值为 400 pM。ARB-272572 hydrochloride 通过诱导 PD-L1 蛋白同源相互作用来抑制 PD-1/PD-L1 细胞信号传导。 | |||
T36899 |
INCB086550
PD-1/PD-L1-IN-8 |
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
INCB086550 (PD-1/PD-L1-IN-8) (example 24) 是 PD-1/PD-L1 的抑制剂,其IC50 值为 <= 10 nM。 | |||
T40111L |
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride 是一种基于间苯二酚二Ph醚支架的程序性细胞死亡-1(PD-1)/程序性细胞死亡配体1(PD-L1)抑制剂, 抑制 PD-1/PD-L1 相互作用,IC50 值为 39.2 nM.BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride 包含靶蛋白 PD-1/PD-L1 配体和 PROTAC linker。BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride 可用于合成 PROTAC PD-1/PD-L1 degrader-1。BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride 具有抗癌活性。BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride 可作为稀释剂,用于用于直接压缩制备片剂。 | |||
T8470 |
BMS-1001
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
BMS-1001 是一种有效的 PD-1/PD-L1 相互作用抑制剂(IC50:2.25 nM,在均相时间分辨荧光结合试验中)。 | |||
T5697 |
BMS-1166
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
BMS-1166 是 PD-1/PD-L1免疫检查点抑制剂。它促使 PD-L1 形成 PD-L1 同源二聚体,进而阻断其与 PD-1 的相互作用,其 IC50为 1.4 nM。它阻断了 PD-1/PD-L1 免疫检查点对 T 细胞活化的抑制作用。 | |||
T9651 |
PD-1/PD-L1-IN-9
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
PD-1/PD-L1-IN-9 是一种有效和具有口服活性的 PD-1/PD-L1 相互作用抑制剂,IC50 值为 3.8 nM。PD-1/PD-L1-IN-9 可以增强免疫细胞对肿瘤细胞的杀伤活性。PD-1/PD-L1-IN-9 在 CT26 小鼠模型中表现出显着的体内抗肿瘤活性。 | |||
T12379 |
PD-1-IN-22
|
Others; PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation; Others |
PD-1-IN-22 是一种有效的程序性细胞死亡 1 (PD-1)/程序性细胞死亡配体1 (PD-L1) 相互作用的抑制剂,IC50 为 92.3 nM。 | |||
T10565 |
BMS-1001 hydrochloride
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
BMS-1001 hydrochloride 是一种人 PD-L1/PD-1免疫检查点的抑制剂,具有口服活性且细胞毒性低。 | |||
T76750 |
Cemiplimab
REGN-2810,SAR-439684 |
Others | Others |
Cemiplimab (Anti-Human PD-1) 是一种针对程序性细胞死亡受体 1 (PD-1) 的人单克隆抗体,也是一种检查点抑制剂,可阻断 PD-1/PD-L1 介导的 T 细胞抑制,可用于转移性癌症和鳞状细胞皮肤癌研究。 | |||
T3468 |
Tomivosertib
eFT508 |
MNK; PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation; MAPK |
Tomivosertib (eFT508) 是一种具有口服活性的MNK1和MNK2高选择性抑制剂,IC50值均为 1-2 nM。它可降低肿瘤细胞中eIF4E 的磷酸化水平 (位点为 Ser209,IC50=2-16 nM),下调PD-L1蛋白的平均含量。 | |||
T64086 |
PD-1/PD-L1-IN-20
|
||
PD-1/PD-L1-IN-20 是一种小分子的 PD-1/PD-L1蛋白-蛋白相互作用抑制剂。PD-1/PD-L1-IN-20 可阻断 PD-1/PD-L1 相互作用 (IC50: 5.29 nM)。PD-1/PD-L1-IN-20 能够用于研究癌症、传染病和自身免疫性疾病。 | |||
T12380 |
PD-1/PD-L1-IN 5 TFA
PD-1/PD-L1-IN 5 |
Others | Others |
PD-1/PD-L1-IN 5 is an inhibitor of PD-1/PD-L1 protein/protein interaction (IC50 of ≤100 nM). | |||
T72724 | PD-1/PD-L1-IN-30 | ||
PD-1/PD-L1-IN-30 是一种 PD-1/PD-L1结合抑制剂,IC50值为 0.018 μM。PD-1/PD-L1-IN-30 可用于癌症及其他相关疾病的研究。 | |||
T63614 | PD-1/PD-L1-IN-15 | ||
PD-1/PD-L1-IN-15 是 PD-1/PD-L1 的有效抑制剂 (IC50: 60.1 nM),对肿瘤免疫治疗表现出研究潜力。 | |||
T36900 |
PD-1/PD-L1-IN-NP19
PD-1/PD-L1-IN-NP19 |
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
PD-1/PD-L1-IN-NP19 是 PD-1/PD-L1 的抑制剂,抑制人类 PD-1/PD-L1 相互作用的 IC50 值为 12.5 nM。PD-1/PD-L1-IN-NP19 可以激活肿瘤的免疫微环境,这可能有助于其抗肿瘤作用。 | |||
T63329 | PD-1/PD-L1-IN-25 | ||
PD-1/PD-L1-IN-25 是一种 PD-1/PD-L1 互作的抑制剂 (IC50: 16.17 nM),可有效激活 PBMCs 中 T 细胞的抗肿瘤免疫。PD-1/PD-L1-IN-25 能够用于研究癌症。 | |||
T70286 | BMS-37 | ||
BMS-37 is a novel inhibitor of PD-1/PD-L1 immune checkpoint. | |||
T72691 |
PD-1/PD-L1-IN-28
|
||
PD-1/PD-L1-IN-28(化合物3),一种针对PD-1/PD-L1信号通路的免疫检查点抑制剂,具IC50值为0.744 µM,展现出在肿瘤免疫治疗领域的研究潜力。 | |||
T69447 |
APBC
|
||
APBC is a novel PD-L1 inhibitor, effectively interrupting the PD-1/PD-L1 interaction by directly binding to PD-L1, presenting the KD and IC50 values at low-micromolar level, displaying superior antitumor efficacy in hPD-L1 knock-in B16F10-bearing mouse model without the induction of observable liver toxicity. | |||
T79576 |
PD-1/PD-L1-IN-32
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
PD-1/PD-L1-IN-32(compound A56)为高效抗PD-1/PD-L1抑制剂,IC50值为2.4 nM,显示出抗癌活性。在hPD-L1 MC38人源化小鼠模型中,该化合物能显著抑制肿瘤生长,同时对小鼠未见明显毒性。 | |||
T82960 |
ASC-69
APY69 |
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
ASC-69 (APY69) 是一种高效的PD-1/PD-L1小分子抑制剂。 | |||
T72680 | PD-1/PD-L1-IN-27 | PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
PD-1/PD-L1-IN-27是一种针对PD-1/PD-L1的有效抑制剂,具有134 nM的IC50值。该化合物表现出具有低T细胞毒性的抗肿瘤活性,并能够激活CD8+T细胞以及减少T细胞耗竭。 | |||
T61574 | PD-L1-IN-1 | ||
PD-L1-IN-1, a powerful PD-L1 inhibitor, demonstrated an IC50 of 115 nM. By forming a robust bond with the PD-L1 protein, PD-L1-IN-1 effectively suppressed tumor growth by enhancing the antitumor immune activity of peripheral blood mononuclear cells in co-cultures with PD-L1 expressing cancer cells (PC9 and HCC827 cells). It significantly elevated the release of interferon γ and induced apoptosis in cancer cells, while exhibiting minimal cytotoxicity in healthy cells [1]. | |||
T72675 |
PD-1/PD-L1-IN-23
|
||
PD-1/PD-L1-IN-23为一种高效的口服活性PD-1/PD-L1抑制剂,是L7酯类的前药形式。L7为苯并[c][1,2,5]恶二唑衍生物,作为PD-L1抑制剂在生物学上进行评估。PD-1/PD-L1-IN-23在同基因和PD-L1人源化小鼠的肿瘤模型中展现出显著的抗肿瘤效果。 | |||
T61968 | PD-1/PD-L1-IN 6 | ||
PD-1/PD-L1-IN 6 (compound A13) 是有效的PD-1/PD-L1相互作用抑制剂(IC50为 132.8 nM)。PD-1/PD-L1-IN 6 显示出显著的免疫调节活性。 在 Hep3B/OS-8/hPD-L1 与 CD3 T 细胞共培养模型中,PD-1/PD-L1-IN 6显著提高干扰素 -γ 分泌,且无明显毒性作用。 在 T 细胞-肿瘤共培养模型中,PD-1/PD-L1-IN 6恢复免疫应答。 | |||
T72670 |
PD-1/PD-L1-IN-13
|
||
PD-1/PD-L1-IN-13 是一种有效的免疫检查点 PD-1/PD-L1抑制剂,对 PD-1/PD- L1 相互作用的 IC50值为 10.2 nM。PD-1/PD-L1-IN-13 在 Hepa1-6 同系小鼠模型中促进 CD8+T 细胞活化并延缓肿瘤生长。 | |||
T76080 |
Human PD-L1 inhibitor V
|
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
V (human PD-L1 inhibitor) 是一种与human PD-1 protein结合的肽,具有3.32 μM的Kd值,能有效抑制PD-1/PD-L1之间的相互作用。 | |||
T76198 |
TPP-1 TFA
|
||
TPP-1 TFA,作为PD-1/PD-L1相互作用的有效抑制剂,特异性与PD-L1高亲和力结合(KD=95 nM)。在动物模型中,其通过再激活T细胞功能来抑制肿瘤生长。 | |||
T63948 | PD-1/PD-L1-IN-16 | ||
PD-1/PD-L1-IN-16 是 PD-1/PD-L1 的有效抑制剂 (IC50: 53.2 nM),对肿瘤免疫治疗表现出研究潜力。 | |||
T72721 | PD-1/PD-L1-IN-29 | ||
PD-1/PD-L1-IN-29(S4-1),有效PD-1/PD-L1抑制剂,IC50值为6.1 nM。能够结合PD-L1,破坏PD-1/PD-L1相互作用,诱导PD-L1二聚化与内化,有助于改善其对内质网的定位并促进PD-L1进入内质网,展现出抗癌活性。 | |||
T14670 |
BMS-1166 hydrochloride
|
Others | Others |
Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM). BMS-1166 hydrochloride is an inhibitor of PD-1/PD-L1 interaction (IC50: 1.4 nM). BMS-1166 rivalries the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation. | |||
T76197 |
TPP-1
|
||
TPP-1 是 PD-1/PD-L1相互作用的有效抑制剂。TPP-1 与 PD-L1特异性高亲和力结合 (KD=95 nM)。动物模型中,TPP-1 通过再激活 T 细胞功能抑制肿瘤生长。 | |||
T70285 |
BMS-200
|
||
BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with IC50 of 80 nM. | |||
T61929 | PD-1/PD-L1-IN-14 | ||
PD-1/PD-L1-IN-14 (compound 17) 是PD-1/PD-L1相互作用的抑制剂(IC50= 27.8 nM)。通过抑制PD-1/PD-L1 相互作用,PD-1/PD-L1-IN-14促进二聚化,内吞作用并降解 PD-L1。 | |||
T23805 |
BMS-242
BMS242 |
||
BMS-242 is an effective inhibitor of PD-1/PD-L1 interaction. | |||
T62193 | PD-1/PD-L1-IN 5 | ||
PD-1/PD-L1-IN 5 是一种有效的 PD-1/PD-L1 蛋白/蛋白相互作用抑制剂 (IC50≤100 nM)。 | |||
T36046 |
LH1306
|
||
LH1306 is an inhibitor of the interaction between programmed cell death 1 (PD-1) and its ligand PD-L1 that has an IC50 value of 25 nM in a homologous time-resolved fluorescence (HTRF) assay.1 It increases the activation of Jurkat cells expressing PD-1 in co-culture with U2OS or CHO cells expressing PD-L1 (EC50s = 334 and 4,214 nM, respectively, in reporter assays). |1. Basu, S., Yang, J., Xu, B., et al. Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibito... | |||
T63607 | PD-1/PD-L1-IN-22 | ||
PD-1/PD-L1-IN-22 是 PD-1/PD-L1 蛋白-蛋白相互作用的小分子抑制剂,能够阻断 PD-1/PD-L1相互作用 (IC50: 0.732 μM)。PD-1/PD-L1-IN-22 能够用于研究癌症、传染病和自身免疫性疾病。 | |||
T62501 | PD-1/PD-L1-IN-17 | ||
PD-1/PD-L1-IN-17 (Compound P20) 是一种有效的 PD-1/PD-L1 抑制剂 (IC50: 26.8 nM)。PD-1/PD-L1-IN-17 是一种很有前途的先导化合物,能够用于 PD-1/PD-L1 相互作用抑制剂的开发。PD-1/PD-L1-IN-17 具有潜力进行癌症疾病的研究。 |